Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00952744 · ClinicalTrials.gov registry record
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
A clinical trial of Acute Coronary Syndromes, sponsored by Brahms.
- Completed
- Registry status
- 2,071
- Enrollment target
- 11
- Study locations
NCT00952744: Completed study of Acute Coronary Syndromes, sponsored by Brahms.
NCT00952744 is a study of Acute Coronary Syndromes that has completed, run by Brahms. The registered enrollment target is 2,071 participants, above the 146-participant average among 3 other Acute Coronary Syndromes trials with a reported enrollment target (1318% higher). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00952744, a study of Acute Coronary Syndromes, has completed, sponsored by Brahms.
- COMPLETED
- Registry status
- 2,071 participants
- Enrollment target
- 11
- Study locations
Study Summary
While troponin is not detectable until several hours after an Acute Myocardial Infarction (AMI), copeptin is expected to be elevated very early after an AMI. A combination of both markers for the diagnosis of AMI early after the event is therefore expected to be advantageous.
Conditions Studied
Study Locations (11)
California
- Stanford University Hospital - Palo Alto
- University of California, San Diego - San Diego
- University of California, San Francisco - San Francisco
Kansas
- Kansas University Medical Center - Kansas City
Maryland
- University of Maryland - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Henry Ford Hospital - Detroit
Minnesota
- Hennepin County Medical Center - Minneapolis
Ohio
- The Cleveland Clinic - Cleveland
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,071 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-10 |
What the finished NCT00952744 record still lists
NCT00952744 is an observational study that tracks outcomes without assigning an intervention. Its 2,071 participants enrollment target places it among the larger protocols in the corpus, above the 146-participant average among 3 other Acute Coronary Syndromes trials with a reported enrollment target (1318% higher).
The record links to 1 condition, with Acute Coronary Syndromes appearing as the primary indexed condition, and to 0 interventions.
NCT00952744 lists 11 locations in 9 states (California, Kansas, Maryland).
Frequently Asked Questions
What is clinical trial NCT00952744 about?
NCT00952744 is a clinical study titled "Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction". While troponin is not detectable until several hours after an Acute Myocardial Infarction (AMI), copeptin is expected to be elevated very early after an AMI. A combination of both markers for the diagnosis of AMI early after the event is therefore expected to be advantageous.
What is the current status of trial NCT00952744?
This trial is currently completed. The enrollment target is 2,071 participants. The study started on 2009-08. Estimated completion is 2011-10.
What conditions does trial NCT00952744 study?
This clinical trial studies the following conditions: Acute Coronary Syndromes.
Who is sponsoring clinical trial NCT00952744?
This trial is sponsored by Brahms, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00952744 being conducted?
This trial has 11 study locations across California, Kansas, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Coronary Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00588068 · 2,070 participants
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
- NCT06666192 · 2,067 participants · NA
The Ohio State University (OSU) SCREEN Community Program
- NCT04373564 · 2,076 participants · Phase 4
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- NCT07168993 · 2,063 participants · NA
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia